Clinical Drug Experience Knowledgebase

acalabrutinib (calquence) (3 trials)

bendamustine (treanda) (12 trials)

chlorambucil (Leukeran) (5 trials)

cyclophosphamide (cytoxan) (14 trials)

darbepoetin alfa (aranesp) (1 trial)

fludarabine (fludara) (17 trials)

ibrutinib (imbruvica) (6 trials)

lenalidomide (revlimid) (2 trials)

mitoxantrone (novantrone) (4 trials)

obinutuzumab (gazyva) (17 trials)

rituximab (rituxan) (12 trials)

sargramostim (leukine) (4 trials)

venetoclax (venclexta) (9 trials)

alemtuzumab (campath) (8 trials)

allogeneic lymphocytes (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

autologous hematopoietic stem cells (3 trials)

bone autograft (1 trial)

busulfan (Myleran) (1 trial)

carmustine (bicnu) (2 trials)

cyclosporine (sandimmune) (1 trial)

cytarabine (cytosar-u) (2 trials)

doxorubicin (Doxil) (1 trial)

eltrombopag (promacta) (1 trial)

entospletinib (1 trial)

Epcoritamab (Epkinly) (1 trial)

etoposide (vepesid) (2 trials)

idelalisib (zydelig) (2 trials)

melphalan (alkeran) (2 trials)

mycophenolate (CellCept) (1 trial)

naltrexone (revia) (2 trials)

ofatumumab (arzerra) (1 trial)

prednisone (meticorten) (1 trial)

sitravatinib (1 trial)

tirabrutinib (2 trials)

tislelizumab (1 trial)

urea (2 trials)

vincristine (oncovin) (1 trial)

zanubrutinib (Brukinsa) (2 trials)